Flight Model Design and Development Status of the Earth - Moon Lagrange Point Exploration CubeSat EQUULEUS Onboard SLS EM-1

EQUULEUS (EQUilibriUm Lunar-Earth point 6U Spacecraft) will be the world’s smallest spacecraft to explore the Earth―Moon Lagrange point. The spacecraft is being jointly developed by JAXA and the University of Tokyo and will be launched by NASA’s SLS (Space Launch System) EM-1 (Exploration Mission-1). The spacecraft will fly to a libration orbit around the Earth―Moon Lagrange point L2 (EML2) and demonstrate trajectory control techniques within the Sun-Earth-Moon region for the first time by a nano spacecraft. This spacecraft also carries several scientific observation missions which will be conducted during and after the flight to EML2; imaging of the entire Earth’s plasmasphere by extreme UV wavelength, observation of the space dust flux in the cis-lunar region, and observation of the lunar meteor impact flashes at the far side of the moon from EML2. The development of the spacecraft started in the summer of 2016 and the engineering model integration and testing was completed by the end of 2017. The design of the flight model was completed based on the engineering model test results. The integration and testing of the flight model will be completed by the end of 2018, to be ready for the launch by SLS’ first flight in 2019

Noninvasive prediction of shunt operation outcome in idiopathic normal pressure hydrocephalus

Idiopathic normal pressure hydrocephalus (iNPH) is a syndrome characterized by gait disturbance, cognitive deterioration and urinary incontinence in elderly individuals. These symptoms can be improved by shunt operation in some but not all patients. Therefore, discovering predictive factors for the surgical outcome is of great clinical importance. We used normalized power variance (NPV) of electroencephalography (EEG) waves, a sensitive measure of the instability of cortical electrical activity, and found significantly higher NPV in beta frequency band at the right fronto-temporo-occipital electrodes (Fp2, T4 and O2) in shunt responders compared to non-responders. By utilizing these differences, we were able to correctly identify responders and non-responders to shunt operation with a positive predictive value of 80% and a negative predictive value of 88%. Our findings indicate that NPV can be useful in noninvasively predicting the clinical outcome of shunt operation in patients with iNPH

Catalogue of Japanese Staphylinidae (Insecta: Coleoptera) : Addition and Corrections until 2014

１.はじめに 2.目録2013年に出版された日本産ハネカクシ科総目録に関して、2014年までの情報をもとに、追加と訂正を行った。今回の追加および訂正により、日本産ハネカクシ科は400属 2,335種 41亜種となったShibata et al. (2013) published “Catalogue of Japanese Staphylinidae (Insecta: Coleoptera)” based on taxonomic information available up until the first half of 2012. In that catalogue were listed 398 genera, 2,268 species and 44 subspecies, together with Japanese names and known distributions of all species/subspecies. Shibata et al. (2014) listed correction to the catalogue. Since the publication of the catalogue, many papers concerning Japanese Staphylinidae were published. These papers included new species, new records, taxonomic changes, and corrections concerning the Japanese staphylinid fauna. This paper lists such additional data published up until the end of 2014. As a result of the additions and corrections, a total number of Japanese Staphylinidae is represented by 400 genera, 2,335 species, and 41 subspecies

日本産ハネカクシ科総目録（昆虫綱：甲虫目） : 2014年までの追加と訂正

2013年に出版された日本産ハネカクシ科総目録に関して、2014年までの情報をもとに、追加と訂正を行った。今回の追加および訂正により、日本産ハネカクシ科は400属 2,335種 41亜種となったShibata et al. (2013) published “Catalogue of Japanese Staphylinidae (Insecta: Coleoptera)” based on taxonomic information available up until the first half of 2012. In that catalogue were listed 398 genera, 2,268 species and 44 subspecies, together with Japanese names and known distributions of all species/subspecies. Shibata et al. (2014) listed correction to the catalogue. Since the publication of the catalogue, many papers concerning Japanese Staphylinidae were published. These papers included new species, new records, taxonomic changes, and corrections concerning the Japanese staphylinid fauna. This paper lists such additional data published up until the end of 2014. As a result of the additions and corrections, a total number of Japanese Staphylinidae is represented by 400 genera, 2,335 species, and 41 subspecies.１.はじめに 2.目

Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study design

Introduction Familial hypercholesterolaemia (FH) is an autosomal-dominant inherited genetic disease. It carries an extremely high cardiovascular risk associated with significantly elevated low-density lipoprotein (LDL) cholesterol. The diagnostic rate of this disease in some European nations is quite high, due to the presence of multiple prospective registries. On the other hand, few data—and in particular multicentre data—exist regarding this issue among Japanese subjects. Therefore, this study intends to assemble a multicentre registry that aims to comprehensively assess cardiovascular risk among Japanese FH patients while taking into account their genetic backgrounds.Methods and analysis The Hokuriku-plus FH registry is a prospective, observational, multicentre cohort study, enrolling consecutive FH patients who fulfil the clinical criteria of FH in Japan from 37 participating hospitals mostly in Hokuriku region of Japan from April 2020 to March 2024. A total of 1000 patients will be enrolled into the study, and we plan to follow-up participants over 5 years. We will collect clinical parameters, including lipids, physical findings, genetic backgrounds and clinical events covering atherosclerotic and other important events, such as malignancies. The primary endpoint of this study is new atherosclerotic cardiovascular disease (ASCVD) events. The secondary endpoints are as follows: LDL cholesterol, secondary ASCVD events and the occurrence of other diseases including hypertension, diabetes and malignancies.Ethics and dissemination This study is being conducted in compliance with the Declaration of Helsinki, the Ethical Guidelines for Medical and Health Research Involving Human Subjects, and all other applicable laws and guidelines in Japan. This study protocol has been approved by the Institutional Review Board at Kanazawa University. We will disseminate the final results at international conferences and in a peer-reviewed journal.Trial registration number UMIN000038210